Skip to content

L · 0QOC.L

HBM Healthcare Investments AG

Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….

Sector
Financial Services · Asset Management
Headquarters
Zug 6301

Price at previous close

$250.50

Market cap 1.57B

Price history

The price history chart is shown only to users with a Pro subscription.

InvestorsCraft valuation

Fair value (AI, DCF / IC, Graham) for HBM Healthcare Investments AG (0QOC.L) is available to Pro members and via the machine API.

  • AI valuation — available
  • Intrinsic / IC value — available
  • Upside vs price — available

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

The valuation history chart is shown only to users with a Pro subscription.

Historic valuation ratios

Pick a category, then toggle metrics to compare.

Historic valuation ratios are shown only to users with a Pro subscription.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About HBM Healthcare Investments AG

        HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.

        CEO
        Andreas Wicki
        Employees
        0
        Beta
        0.92

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.